{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["Sheet 0"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":0,"defined_names":0,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"Sheet 0","index":0,"n_rows":53,"n_cols":5,"rows_kept":53,"cut":false,"hidden":false,"merged":[[2,3,2,4]],"flags":["formulas_cached_only"]}
["Supplementary Table2. Total list of GeneGo Pathways analysis of genes affected in all three clones"]
[]
["#","Maps","pValue","Ratio"]
[1,"wtCFTR and delta508 traffic / Clathrin coated vesicles formation (norm and CF)",0.01082,1,19]
[2,"Development_EGFR signaling via PIP3",0.01308,1,23]
[3,"Development_Dopamine D2 receptor transactivation of EGFR",0.01365,1,24]
[4,"Transport_RAB5A regulation pathway",0.01421,1,25]
[5,"G-protein signaling_K-RAS regulation pathway",0.01421,1,25]
[6,"Neurophysiological process_GABA-A receptor life cycle",0.01534,1,27]
[7,"Development_Mu-type opioid receptor regulation of proliferation",0.01591,1,28]
[8,"Transcription_Ligand-dependent activation of the ESR1/SP pathway",0.01704,1,30]
[9,"Development_Angiotensin activation of ERK",0.01873,1,33]
[10,"LRRK2 in neurons in Parkinson's disease",0.01873,1,33]
[11,"G-protein signaling_N-RAS regulation pathway",0.01873,1,33]
[12,"Development_EGFR signaling via small GTPases",0.01873,1,33]
[13,"Inhibitory action of Lipoxin A4 on PDGF, EGF and LTD4 signaling",0.01985,1,35]
[14,"Development_Lipoxin inhibitory action on PDGF, EGF and LTD4 signaling",0.02041,1,36]
[15,"Development_Beta-adrenergic receptors transactivation of EGFR",0.02098,1,37]
[16,"Development_Delta-type opioid receptor mediated cardioprotection",0.02098,1,37]
[17,"Glycogen metabolism",0.02154,1,38]
[18,"Cell adhesion_PLAU signaling",0.0221,1,39]
[19,"Development_ERBB-family signaling",0.0221,1,39]
[20,"Translation _Regulation of EIF2 activity",0.0221,1,39]
[21,"Translation_Non-genomic (rapid) action of Androgen Receptor",0.02266,1,40]
[22,"Apoptosis and survival_BAD phosphorylation",0.02378,1,42]
[23,"Pentose phosphate pathway/ Rodent version",0.02434,1,43]
[24,"Development_ACM2 and ACM4 activation of ERK",0.02434,1,43]
[25,"Development_Activation of Erk by ACM1, ACM3 and ACM5",0.02491,1,44]
[26,"Pentose phosphate pathway",0.02491,1,44]
[27,"Immune response_IL-13 signaling via JAK-STAT",0.02491,1,44]
[28,"Transcription_Androgen Receptor nuclear signaling",0.02547,1,45]
[29,"Development_Ligand-independent activation of ESR1 and ESR2",0.02547,1,45]
[30,"Role of alpha-6/beta-4 integrins in carcinoma progression",0.02547,1,45]
[31,"Neurophysiological process_Receptor-mediated axon growth repulsion",0.02547,1,45]
[32,"Signal transduction_PTEN pathway",0.02603,1,46]
[33,"Development_Endothelin-1/EDNRA transactivation of EGFR",0.02603,1,46]
[34,"Development_Angiotensin activation of Akt",0.02603,1,46]
[35,"Glycolysis and gluconeogenesis p. 1",0.02603,1,46]
[36,"Development_WNT5A signaling",0.026590000000000003,1,47]
[37,"Mucin expression in CF via TLRs, EGFR signaling pathways",0.02826,1,50]
[38,"wtCFTR and delta508-CFTR traffic / Generic schema (norm and CF)",0.02826,1,50]
[39,"Some pathways of EMT in cancer cells",0.02882,1,51]
[40,"Cell adhesion_ECM remodeling",0.02938,1,52]
[41,"Translation _Regulation of EIF4F activity",0.02994,1,53]
[42,"Development_WNT signaling pathway. Part 2",0.02994,1,53]
[43,"Membrane-bound ESR1: interaction with G-proteins signaling",0.0305,1,54]
[44,"PGE2 pathways in cancer",0.031049999999999998,1,55]
[45,"Development_Gastrin in cell growth and proliferation",0.03495,1,62]
[46,"Muscle contraction_Oxytocin signaling in uterus and mammary gland",0.03495,1,62]
[47,"Development_Alpha-2 adrenergic receptor activation of ERK",0.03495,1,62]
[48,"Development_EGFR signaling pathway",0.03551,1,63]
[49,"Transport_Macropinocytosis regulation by growth factors",0.03551,1,63]
[50,"Development_Regulation of epithelial-to-mesenchymal transition (EMT)",0.03606,1,64]